FindTrial
Sign In

Scottish Post Menopausal Chemo-Endocrine Trial

Scottish Post Menopausal Chemo-Endocrine Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN51555498
Enrollment
Unknown
Registered
2002-08-19
Start date
1995-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

Following surgery patients are randomised to one of two treatment groups: 1. Group A: Tamoxifen 20 mg daily for 5 years 2. Group B: Tamoxifen 20 mg daily for 5 years plus six cycles of CMF (cyclophos

Sponsors

Scottish Cancer Therapy Network (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed invasive carcinoma of the breast 2. Post-menopausal 3. Aged <70 years 4. No medical contraindications to treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026